News from viacyte, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 29, 2015, 09:00 ET
ViaCyte logo.

ViaCyte Announces Second Clinical Trial Site at University of Alberta

Dr. James Shapiro, who led the team that developed the "Edmonton Protocol," will be lead investigator at the Canadian site  ViaCyte, Inc.,...

Jun 16, 2015, 09:00 ET
ViaCyte logo.

ViaCyte to Present Plenary Lecture at ISSCR 2015 Annual Meeting

 ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the...

May 14, 2015, 09:00 ET
ViaCyte logo

ViaCyte to Present at London Regenerative Medicine Network and The World Stem Cells and Regenerative Medicine Congress 2015

ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of...

May 11, 2015, 09:00 ET
ViaCyte logo.

ViaCyte to Present at Cavendish Global Health Impact Forum

 ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the...

Apr 23, 2015, 09:00 ET
ViaCyte logo.

ViaCyte to Present at GTCbio 2015 Diabetes Summit

ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the...

Mar 17, 2015, 09:00 ET
ViaCyte logo.

ViaCyte to Present at ARM's Third Annual Regen Med Investor Day

 ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of...

Mar 03, 2015, 09:00 ET
ViaCyte logo.

ViaCyte to Present at JDRF TypeOneNation Research Summit

SAN DIEGO and BETHESDA, Md., March 3, 2015 /PRNewswire/-- ViaCyte, Inc., a privately-held regenerative medicine company with the first stem...

Feb 25, 2015, 09:00 ET
ViaCyte logo

ViaCyte to Present at 35th Annual Cowen and Company Health Care Conference

ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of...

Feb 23, 2015, 09:00 ET
ViaCyte logo.

ViaCyte to Present at Two San Diego Events: Biocom's Global Life Science Partnering Conference and UCSD Diabetes Public Forum

 ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of...

Jan 12, 2015, 09:15 ET
ViaCyte logo.

JDRF Honors Current and Former ViaCyte Team with Top Scientific Excellence Award

 ViaCyte and JDRF announced today that the current and former ViaCyte team are being recognized by JDRF for their pioneering work in developing...

Jan 08, 2015, 09:00 ET
ViaCyte logo.

ViaCyte Receives Clearance from Health Canada for Diabetes Clinical Trial

ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of...

Dec 22, 2014, 09:00 ET
ViaCyte logo.

ViaCyte to Present at Biotech Showcase in San Francisco

 ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of...

Dec 18, 2014, 09:00 ET
ViaCyte logo.

Study Further Validates Cell Therapy Approach to Reverse Type 1 Diabetes

ViaCyte, Inc. announced today a preclinical study published online in Cell Stem Cell that describes a novel approach to replace the...

Nov 20, 2014, 09:00 ET
ViaCyte logo.

ViaCyte to Present at 26th Annual Piper Jaffray Healthcare Conference

ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of...

Nov 06, 2014, 09:00 ET
After implant into animals in pre-clinical studies of VC-01, the PEC-01 cells mature into the various human cell types of the endocrine pancreas, including those expressing insulin (INS, blue), glucagon (GCG, red), and somatostatin (SST, green).

ViaCyte Receives U.S. Patent Claiming Alternative Methods to Manufacture Pancreatic Progenitor Cells In Vitro

 ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of...

Oct 29, 2014, 09:00 ET
ViaCyte logo.

ViaCyte's VC-01™ Investigational Stem Cell-Derived Islet Replacement Therapy Successfully Implanted into First Patient

ViaCyte, Inc., a privately-held regenerative medicine company, announced today that the first patient in its Phase 1/2 study was successfully...

Oct 06, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte, Inc. to Present at Upcoming Stem Cell Meeting on the Mesa Conference

ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of...

Sep 10, 2014, 15:21 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte, Inc. Awarded $16.6 Million Accelerated Development Pathway Grant from CIRM to Expand Clinical Development of its VC-01™ Diabetes Therapy Candidate

 ViaCyte, Inc., a privately held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of...

Aug 21, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte, Inc. Announces Signing of Rights Agreement with Janssen Research & Development LLC.

ViaCyte, Inc., a privately held regenerative medicine company announced today that it has entered into a Rights Agreement with Janssen Research...

Aug 19, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte, Inc. Announces FDA Acceptance of IND to Commence Clinical Trial of VC-01™ Candidate Cell Replacement Therapy for Type 1 Diabetes

ViaCyte, Inc., a privately-held regenerative medicine company, announced today that the U.S. Food and Drug Administration ("FDA") has accepted the...